Despite its potential, active targeting faces several challenges:
1. Biocompatibility: Ensuring that nanoparticles are non-toxic and do not elicit an immune response. 2. Stability: Maintaining the stability of nanoparticles and their functional ligands in the bloodstream. 3. Manufacturing: Producing nanoparticles with uniform size and ligand attachment. 4. Regulatory Hurdles: Navigating the complex regulatory landscape for clinical approval.
